May 21 Clinical Quick Takes: Array gains on colorectal cancer plans; plus Tocagen, Promedior

Array planning submissions for colorectal cancer triplet
Array BioPharma Inc. (NASDAQ:ARRY) gained $4.81 (23%) to $25.77 on Tuesday after interim data from the Phase III BEACON CRC trial to treat BRAF

Read the full 303 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE